Makurvet FD. Biologics vs. small molecules: drug costs and patient access. Med Drug Discov. 2021;9:100075.

Article  CAS  Google Scholar 

US FDA. What are “Biologics” questions and answers. FDA; 2019 [cited 2022 Jul 14]. Available at: https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/what-are-biologics-questions-and-answers.

Doshi JA, Li P, Ladage VP, Pettit AR, Taylor EA. Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions. Am J Manag Care. 2016;22:188–97.

PubMed  Google Scholar 

Lexchin J. Affordable biologics for all. JAMA Netw Open. 2020;3: e204753.

Article  PubMed  Google Scholar 

US FDA. Biosimilar and interchangeable products. FDA; 2019 [cited 2022 May 12]. Available at: https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products.

Simoens S, Vulto AG. A health economic guide to market access of biosimilars. Expert Opin Biol Ther. 2021;21:9–17.

Article  PubMed  Google Scholar 

Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States. Rand Health Q. 2018;7:3.

PubMed  PubMed Central  Google Scholar 

Zhai MZ, Sarpatwari A, Kesselheim AS. Why are biosimilars not living up to their promise in the US? AMA J Ethics. 2019;21:668–78.

Article  Google Scholar 

San-Juan-Rodriguez A, Gellad WF, Good CB, Hernandez I. Trends in list prices, net prices, and discounts for originator biologics facing biosimilar competition. JAMA Netw Open. 2019;2: e1917379.

Article  PubMed  PubMed Central  Google Scholar 

Chen AJ, Ribero R, Van Nuys K. Provider differences in biosimilar uptake in the Filgrastim Market. Am J Manag Care. 2020;26:208–13.

Article  PubMed  Google Scholar 

Chopra R, Lopes G. Improving access to cancer treatments: the role of biosimilars. J Glob Oncol. 2017;3:596–610.

Article  PubMed  PubMed Central  Google Scholar 

Baker JF, Leonard CE, Lo Re III V, Weisman MH, George MD, Kay J. Biosimilar uptake in Academic and Veterans Health Administration settings: influence of institutional incentives. Arthritis Rheumatol. 2020;72:1067–71.

Article  PubMed  PubMed Central  Google Scholar 

Dutcher SK, Fazio-Eynullayeva E, Eworuke E, Carruth A, Dee EC, Blum MD, et al. Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness. Pharmacoepidemiol Drug Saf. 2020;29:786–95.

Article  CAS  PubMed  Google Scholar 

Chambers JD, Lai RC, Margaretos NM, Panzer AD, Cohen JT, Neumann PJ. Coverage for biosimilars vs reference products among US commercial health plans. JAMA. 2020;323:1972–3.

Article  PubMed  PubMed Central  Google Scholar 

Ventola CL. Biosimilars. Part 2: potential concerns and challenges for P&T committees. P T. 2013;38:329–35.

Chambers JD, Kim DD, Pope EF, Graff JS, Wilkinson CL, Neumann PJ. Specialty drug coverage varies across commercial health plans in the US health affairs. Health Aff. 2018;37:1041–7.

Article  Google Scholar 

Margaretos NM, Bawa K, Engmann NJ, Chambers JD. Patients’ access to rare neuromuscular disease therapies varies across US private insurers. Orphanet J Rare Dis. 2022;17:36.

Article  PubMed  PubMed Central  Google Scholar 

Tufts, Center for the Evaluation of Value and Risk. SPEC Database [cited 2022 Mar 26]. Available at: https://cevr.tuftsmedicalcenter.org/databases/spec-database.

Tufts, Center for the Evaluation of Value and Risk. Cost-Effectiveness Analysis (CEA) Registry Updated Through 2019 [cited 2022 Mar 26]. Available at: https://cevr.tuftsmedicalcenter.org/news/2020/cea-registry-updated-through-2019.

IBM. Micromedex RED BOOK. 2022 [cited 2022 Apr 20]. Available at: https://www.ibm.com/products/micromedex-red-book.

Lenahan KL, Nichols DE, Gertler RM, Chambers JD. Variation in use and content of prescription drug step therapy protocols, within and across health plans. Health affairs. Health Aff. 2021;40:1749–57.

Article  Google Scholar 

Chambers JD, Margaretos NM, Enright DE, Wang R, Ye X. Is an orphan drug’s cost-effectiveness associated with US Health Plan Coverage restrictiveness? Pharmacoeconomics. 2022;40:225–32.

Article  PubMed  Google Scholar 

Patel D, Shelbaya A, Cheung R, Aggarwal J, Park SH, Coindreau J. Cost-effectiveness of early treatment with originator biologics or their biosimilars after methotrexate failure in patients with established rheumatoid arthritis. Adv Ther. 2019;36:2086–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schulman KA, Dabora M. The relationship between pharmacy benefit managers (PBMs) and the cost of therapies in the US pharmaceutical market: a policy primer for clinicians. Am Heart J. 2018;206:113–22.

Article  PubMed  Google Scholar 

Fein AJ. The top pharmacy benefit managers of 2021: the big get even bigger [cited 2022 Jun 22]. Available at: https://www.drugchannels.net/2022/04/the-top-pharmacy-benefit-managers-of.html.

Pharmaceutical Care Management Association. Biosimilars versus biologics—how about both? 2021 [cited 2022 Jun 28]. Available at: https://www.pcmanet.org/biosimilars-versus-biologics-how-about-both/.

Sohn M. Chapter 56—drug distribution system. In: Adejare A (ed) Remington, 23rd edn. Academic Press; 2021 [cited 2022 Dec 24], pp. 967–74. Available at: https://www.sciencedirect.com/science/article/pii/B9780128200070000544.

Tjalma W, Huizing M, Papadimitriou K. The smooth and bumpy road of trastuzumab administration: from intravenous (IV) in a hospital to subcutaneous (SC) at home. Facts Views Vis Obgyn. 2017;9:51–5.

PubMed  PubMed Central  Google Scholar 

Epstein RS. Payer perspectives on intravenous versus subcutaneous administration of drugs. Clinicoecon Outcomes Res. 2021;13:801–7.

Article  PubMed  PubMed Central  Google Scholar 

US FDA. Biosimilar and interchangeable biologics: more treatment choices. FDA; 2021 [cited 2022 Apr 23]. Available at: https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices.

Chen AJ, Bhanot P, Gascue L, Ribero R, Shane R, Van Nuys K. Insurer formularies complicate the adoption of biosimilar cancer therapies [cited 2022 Jul 14]. Available at: https://doi.org/10.1377/forefront.20210405.345071/full/.

Chung A, MacEwan J, Goldman DP. Does a ‘One-Size-Fits-All’ formulary policy make sense? Health Affairs. 2016 [cited 2022 Apr 24]. Available at: https://doi.org/10.1377/forefront.20160602.055116/full/.

Abrams L. Biosimilars and exclusive dealing antitrust law: the case of Pfizer Inc v Johnson & Johnson et al. Rochester: Social Science Research Network; 2017 Oct. Report No.: 3066462. Available at: https://papers.ssrn.com/abstract=3066462.

Caves K, Singer H. Assessing bundled and share-based loyalty rebates: application to the pharmaceutical industry. J Compet Law Econ. 2012;8:889–913.

Article  Google Scholar 

Caves KW, Singer HJ. Bundles in the pharmaceutical industry: a case study of pediatric vaccines. Rochester: Social Science Research Network; 2011 Aug. Report No.: 1908306. Available at: https://papers.ssrn.com/abstract=1908306.

Vulto AG, Crow SA. Risk management of biosimilars in oncology: each medicine is a work in progress. Targ Oncol. 2012;7:43–9.

Article  Google Scholar 

Locatelli F, Del Lucia V, Pozzoni P. Pure red-cell aplasia “Epidemic”—mystery completely revealed? Perit Dial Int. 2007;27:303–7.

Article  Google Scholar 

Neumann PJ, Bliss SK, Chambers JD. Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries. Health Aff (Millwood). 2012;31:700–8.

Article  PubMed  Google Scholar 

Wang A, Halbert RJ, Baerwaldt T, Nordyke RJ. US payer perspectives on evidence for formulary decision making. J Oncol Pract. 2012;8:22s-s27.

Article  PubMed  PubMed Central  Google Scholar 

Oskouei ST, Kusmierczyk AR. Biosimilar uptake: the importance of healthcare provider education. Pharmaceut Med. 2021;35:215–24.

PubMed  PubMed Central  Google Scholar 

Edgar BS, Cheifetz AS, Helfgott SM, Smith GP, Bandekar T, Hoye-Simek A, et al. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative. J Manag Care Spec Pharm. 2021;27:1129–35.

PubMed  Google Scholar 

Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: how can payers get long-term savings? Pharmacoeconomics. 2016;34:609–16.

Article  PubMed  PubMed Central  Google Scholar 

Chambers JD, Ari D. Panzer BS, David D. Kim P, Nikoletta M. Margaretos BA, Peter J. Neumann S. Variation in US Private Health Plans’ coverage of orphan drugs. Am J Manag Care. 2019 [cited 2022 Apr 23];25. Available at: https://www.ajmc.com/view/variation-in-us-private-health-plans-coverage-of-orphan-drugs.

Hakim A, Ross JS. Obstacles to the adoption of biosimilars for chronic diseases. JAMA. 2017;317:2163–4.

Article  PubMed  Google Scholar 

Brogan AP, Hogue SL, Vekaria RM, Reynolds I, Coukell A. Understanding payer perspectives on value in the use of pharmaceuticals in the United States. J Manag Care Spec Pharm. 2019;25:1319–27.

PubMed  Google Scholar 

Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108:734–55.

Article  PubMed  PubMed Central  Google Scholar 

Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals. 2016;44:257–66.

Article  PubMed  Google Scholar 

Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332:699–703.

Article  PubMed  PubMed Central  Google Scholar 

Seeley E, Kesselheim AS. Pharmacy benefit managers: practices, controversies, and what lies ahead. Issue Brief (Commonw Fund). 2019;2019:1–11.

PubMed  Google Scholar 

Fein AJ. Why PBMs and payers are embracing insulin biosimilars with higher prices—and what that means for Humira (rerun) [cited 2022 Jun 28]. Available at: https://www.drugchannels.net/2022/04/why-pbms-and-payers-are-embracing.html.

Trifilio S, Zhou Z, Galvin J, Fong JL, Monreal J, Mehta J. Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question. Clin Transplant. 2015;29:1128–32.

Article  CAS  PubMed  Google Scholar 

Morgan SG, Vogler S, Wagner AK. Payers’ experiences with confidential pharmaceutical price discounts: a survey of public and statutory health systems in North America, Europe, and Australasia. Health Policy. 2017;121:354–62.

Article  PubMed  Google Scholar 

Saldarriaga EM, Hauber B, Carlson JJ, Barthold D, Veenstra DL, Devine B. Assessing payers’ preferences for real-world evidence in the United States: a discrete choice experiment. Value Health. 2022;25:443–50.

Article  PubMed  Google Sc